A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sponsor: BioCryst Pharmaceuticals
Terminated
Sponsor decision
Other terminated trials from BioCryst Pharmaceuticals
Listed as NCT04702568, this PHASE2 trial focuses on PNH and Paroxysmal Nocturnal Hemoglobinuria and remains terminated or withdrawn. Sponsored by BioCryst Pharmaceuticals, it has been updated 8 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE2
-
Jan 2025 — May 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 3 earlier versions
-
May 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — May 2023 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2021 — Mar 2022 [monthly]
Enrolling By Invitation PHASE2
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioCryst Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .